|Bid||4.0500 x 3100|
|Ask||5.2500 x 800|
|Day's Range||4.6800 - 4.9100|
|52 Week Range||3.7200 - 9.4800|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MOUNTAIN VIEW, Calif., April 18, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2019 after the.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term IRIDEX Corpor...
IRIDEX Corporation (IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Ken Ludlum has been appointed to its Board of Directors, effective immediately. Ludlum brings a wealth of relevant experience in the medical technology sector, which includes leadership roles as board member, executive officer, investor, and advisor. He currently serves on the board and as Chairman of the Audit Committee at NATUS Medical, a publicly held medical device company and at Personalis, Inc., a venture backed molecular diagnostics company. Previously, Ludlum served on the board of directors for Novacept Corporation, Thermage Corporation, AtheroMed, Bridgeway Plan for Health and Kinetikos Medical.
MOUNTAIN VIEW, Calif., April 01, 2019 -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and.
IRIDEX Corp designs, manufactures, and markets laser equipment used in the ophthalmologic and aesthetic fields. Warning! GuruFocus has detected 3 Warning Signs with IRIX. For the last quarter IRIDEX Corp reported a revenue of $11.5 million, compared with the revenue of $10.24 million during the same period a year ago.
MOUNTAIN VIEW, Calif., March 18, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming Spring Investor Summit in New York, NY..
MOUNTAIN VIEW, Calif., March 06, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming 31st Annual Roth Conference in Orange.
MOUNTAIN VIEW, Calif., March 05, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018..
Upland Software's (UPLD) fourth-quarter 2018 results are expected to benefit from solid adoption of the UplandOne operating platform and recurring revenue growth.
MOUNTAIN VIEW, Calif., Feb. 26, 2019 -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year 2018.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you want to know who really controls IRIDEX CorporationRead More...
IRIDEX Corporation (IRIX) today announced that it has resolved its differences with Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. (collectively, “Quantel”) in its lawsuit filed against Quantel in the U.S. District Court for the Northern District of California. IRIDEX dismissed the lawsuit it had filed in January 2018, alleging that Quantel products infringed IRIDEX’s U.S. Patent No. 7,771,417, that Quantel breached an earlier agreement between the parties, and that Quantel infringed IRIDEX’s MicroPulse® U.S. Trademark, Registration No. 4550188 on the principal register.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
IRIDEX Corporation (IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018. “Our fourth quarter results completed an exciting year for IRIDEX. Our commercial teams continued to drive growth in Cyclo G6 placements and we shipped a record number of G6 probes in the quarter.
The direct benefit for IRIDEX Corporation (NASDAQ:IRIX), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off is Read More...
IRIDEX Corporation (IRIX) today announced Chief Financial Officer Atabak Mokari will leave the Company for a senior finance executive role at another company. Mokari has agreed to assist in the orderly transition of his CFO responsibilities and will leave the Company effective December 18, 2018. IRIDEX plans to search for a replacement.
NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
If you are currently a shareholder in IRIDEX Corporation (NASDAQ:IRIX), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. Read More...
Iridex (IRIX) delivered earnings and revenue surprises of 10.34% and 17.40%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Mountain View, California-based company said it had a loss of 26 cents. The medical laser company posted revenue of $11.3 million in the period. Iridex expects full-year revenue ...
MOUNTAIN VIEW, Calif., Nov. 01, 2018 -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 29, 2018..